---
date: 2020-09-07
---

# fibromyalgia vs polymyositis vs polymyalgia rheumatica

- Keywords:: [[Step 3]], [[Allergy and Immunology]]
---

<!-- fibromyalgia vs polymyositis vs polymyalgia rheumatica -->

| Ddx                        |                                                              |                                                              |
| -------------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ |
|                            | **Clinical features**                                        | **Diagnosis**                                                |
| **Fibromyalgia**           | Young to middle-aged women<br/>Chronic **widespread pain**<br/>Fatigue, impaired concentration<br/>Tenderness at trigger points (eg, mid trapezius, costochondral junction) | >3 months of symptoms with **widespread pain index** or **symptom severity score**<br/>**Normal** laboratory studies |
| **Polymyositis**         | Proximal muscle **weakness** (eg, increasing difficulty climbing up stairs)<br/>Pain mild/absent | **Elevated muscle enzymes** (eg, creatine kinase, aldolase, AST) <br/>Autoantibodies (ANA, anti-Jo-1)<br/>Biopsy: Endomysial infiltrate, patchy necrosis |
| **Polymyalgia rheumatica** | **Age >50**<br/>Systemic signs & symptoms<br/>**Stiffness** > pain in shoulders, hip girdle, neck<br/>Association with giant cell (temporal) arteritis | **Elevated ESR, C-reactive protein**<br/>Rapid improvement with glucocorticoids |

- [[polymyositis and dermatomyositis|Polymyositis]]: Involvement of upper esophageal musculature can cause **dysphagia** with regurgitation and aspiration. Initial remission can be induced with **glucocorticoids** (eg, prednisone), and most patients also receive a **glucocorticoid-sparing agent** (eg, methotrexate, azathioprine) to minimize the long-term adverse effects of treatment.
